focus -WSS

focus

author：entertainment 2025-10-04 08:59:06 - browse：57

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： BMS, looking to build heart drug business, turns to AI for diagnosis

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

Surge in Apellis stock fueled by confidence in safety of its eye drug

Novo Nordisk touts Wegovy study, but still struggling with supply

After Optum profits sink, UnitedHealth makes changes

YouTube cracks down on misinformation on cancer treatment

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

knowledge

focus

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

DIEP, the 'gold standard' of breast reconstruction, is under threat

Letters to First Opinion on caregivers, digital health, and more

The high cost of giving birth even with insurance

YouTube cracks down on misinformation on cancer treatment

State Dept. review finds Biden bears some blame for Afghanistan failures

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Supreme Court strikes down use of affirmative action

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

Aspartame and sugar

ASCO: Palliative care found as helpful given virtually as in person

Shifting the focus from loneliness to social health

BMS, looking to build heart drug business, turns to AI for diagnosis

Biogen’s boardroom scandal saddles CEO with first crisis

ASCO: Palliative care found as helpful given virtually as in person

leisure time

leisure time

knowledge

Wikipedia